• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6

0
  • by alexperjescuadmin
  • in AJO · ASCO · Oncology
  • — 5 Jun, 2006
ASCO Audio Journal of Oncology - June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
AudioMedica News
ASCO Audio Journal of Oncology - June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
ASCO Audio Journal of Oncology - June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
00:00 /
RSS Feed
Share
Link
Embed
Robert Mayer
Robert Mayer
Thierry Facon
Thierry Facon
 Ibrahim Yakoub-Agha
Ibrahim Yakoub-Agha
Peter Paschka
Peter Paschka

Robert Mayer of the Dana-Farber Cancer Institute in Boston joins Derek Thorne to discuss the major hematologic malignancy news reported at the 2006 ASCO meeting.

– Older patients with multiple myeloma can benefit from adding thalidomide to their standard therapy of melphalan and prednisone; and the thalidomide regimen is also better than melphalan followed by autologous stem cell transplantation. Thierry Facon from the University of Lille told ASCO delegates about his group’s findings (Abstract 1)
– A decreased dose of thalidomide may be just as effective in multiple myeloma while having a better side effect profile – but should these results change practice? Ibrahim Yakoub-Agha from the University of Lille had the data at ASCO (Abstract 7520)
– Imatinib is still proving effective at treating chronic myeloid leukemia, even after more than 5 years of follow up. Robert Mayer describes the latest findings from the IRIS study
– In the “core-binding factor” subtype of acute myeloid leukemia, certain mutations in the KIT gene predict for a poor prognosis. This could help tailor therapy for this disease, according to Peter Paschka of Ohio State University


[audio:https://www.audiomedica.com/podcasting/asco/06.06.06_ASCO_podcast.mp3]
Share

Tags: hematologicleukemiamyelomatransplantationtrial

You may also like...

  • Geoffrey J Lindeman BSc (Med) PhD, from the University of Melbourne and the Walter and Eliza Hall Institute of Medical Research and the Familial Cancer Centre at The Royal Melbourne Hospital, Australia BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer 27 Mar, 2015
  • Audio Journal of Gastrointestinal Cancer Special Edition 2005 Audio Journal of Gastrointestinal Cancer Special Edition 2005 8 Jan, 2006
  • Audio Journal of Oncology 12.7, September 2004 Audio Journal of Oncology 12.7, September 2004 8 Sep, 2004
  • Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer 2 Nov, 2007

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story ASCO Audio Journal of Oncology – June 5th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
  • Next story Audio Journal of Oncology – June 7th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • New Front Line Standard for Older Patients with…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Pembrolizumab: No Survival Gains Second Line In…
  • Home
  • Oncology
  • AJO
  • ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.